Company Overview

Natco Pharma Limited (Scrip Code: 524816) submitted an Investor Presentation dated August 2026 to BSE Ltd. and National Stock Exchange of India Ltd pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015. The document was signed by Ch. Venkat Ramesh, Company Secretary & Compliance Officer, on 19th August 2026.

Business Highlights

  • Global revenues for FY26 stood at INR 43,759 Million with state-of-the-art manufacturing facilities including 2 USFDA-approved API and 2 USFDA-approved FDF plants.
  • Among top 10 generic companies by sales in Canada per IQVIA MAT Q4 2025 data.
  • Maintains 5,000+ employees globally with 2 R&D centers and 500+ scientists.

Key Business Segments - FY26 Performance

  • Export Formulations: INR 32,345 Mn revenue. Focus on niche opportunities in US, Canada, Brazil and emerging markets with Para IV and First-to-File molecules.
  • Domestic Formulations: INR 4,409 Mn revenue. 20+ brands in #1 position in indicated prescription with 900+ sales force and 1000+ distributors.
  • API Business: INR 2,347 Mn revenue. Focus on complex oncology molecules with portfolio of 45 active US DMFs.
  • Crop Health Sciences (CHS): INR 1,382 Mn revenue. Launched Chlorantraniliprole (CTPR) products and Glanz fungicide. Board approved demerger of CHS business.

US Market Portfolio & Pipeline

Key Products: Revlimid (Lenalidomide), Copaxone (Glatiramer Acetate), Tamiflu (Oseltamivir), Afinitor (Everolimus), Forsrenol (Lanthanum Carbonate), Tykerb (Lapatinib), Zortress (Everolimus), Valium (Diazepam).

Pipeline Highlights:

  • 28 Para IVs in pipeline with over 20 FTFs (including Sole and Shared)
  • 17 products approved (tentative or fully)
  • Key Solo FTFs: Kyprolis (Carfilzomib), Imbruvica (Ibrutinib), Zydelig (Idelalisib), Lynparza (Olaparib), Semaglutide pen (Ozempic strengths), Balversa (Erdafitinib), Wegovy (Semaglutide), Tabrecta (Capmatinib)
  • Key Para IV NCE-1 filings: Eliquis (Apixaban), Ozempic (Semaglutide), Lonsurf (Trifluridine/Tipiracil), Yondelis (Trabectedin), Acalabrutinib (Calquence), Kyprolis (Carfilzomib 60mg/ml), Nurtec (Rimegepant), Jevtana (Cabazitaxel), Everysdi (Risdiplam)

International Expansion

  • Canada: Single source for Everolimus for fourth consecutive year, launched Carfilzomib and Eltrombopag
  • Brazil: Launched Apixaban among first to launch with highest market share
  • Emerging Markets: Expanding in MENA region, won tenders in Saudi Arabia, Algeria, Egypt, Hong Kong, Ukraine, Thailand
  • China: Launched Oseltamivir capsules (first product), and two oncology products Abiraterone & Gefitinib tablets

Strategic Investments

  • eGenesis: Invested US$8M in xenotransplantation biotechnology. FDA cleared Phase 1/2/3 clinical study for kidney xenotransplantation (33-patient trial starting early 2027).
  • NRC-2694-A: Orally administered tyrosine kinase inhibitor for Head & Neck cancer. Phase 2 trial approved by US FDA, recruitment in progress in US and India.
  • Cellogen Therapeutics: Invested US$2M focused on CAR-T cell therapies for leukemia/lymphoma. First human dosing in India shortly, received GMP approvals.
  • Stero Therapeutics: Invested US$1M focused on metabolic diseases (Cushing's syndrome, NASH), conducting pre-clinical studies.

Financial Performance - FY26 & Q1FY27

Consolidated Revenue Breakdown (INR Mn):

| Segment | Q1FY27 | Q1FY26 | Q4FY26 | FY25 | FY26 |

| API Revenue | 667 | 526 | 639 | 2,018 | 2,347 |

| Domestic Formulations | 1,364 | 1,070 | 1,087 | 4,000 | 4,409 |

| International Formulations | 4,771 | 11,265 | 5,231 | 37,597 | 32,345 |

| CHS | 408 | 347 | 226 | 598 | 1,382 |

| Other income | 734 | 754 | 986 | 3,627 | 3,275 |

| Total Revenue | 7,944 | 13,906 | 8,169 | 47,840 | 43,759 |

Profit & Loss (INR Mn):

  • EBITDA: Q1FY27: 2,457 (30.9% margin), Q1FY26: 6,327 (45.5%), FY26: 17,341 (39.6%)
  • PAT: Q1FY27: 2,065, Q1FY26: 4,803, FY26: 14,185 (32.4% margin)
  • EPS: FY26: INR 79.20 (basic and diluted)
  • One-time tax benefit: INR 1,150 Mn from transition to new tax regime and remeasurement of deferred tax asset on MAT credit

Balance Sheet (as of March 31, 2026):

  • Total Assets: INR 110,737 Mn
  • Property, Plant & Equipment: INR 25,454 Mn
  • Investments: INR 2,732 Mn
  • Cash & Bank Balances: INR 15,509 Mn
  • Total Equity: INR 92,211 Mn
  • Borrowings: Current: INR 6,064 Mn, Non-current: INR 1,000 Mn

Historical Performance (INR Mn)

| Metric | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |

| Revenue | 21,557 | 20,438 | 28,117 | 41,269 | 47,840 | 43,759 |

| EBITDA | 7,098 | 3,625 | 10,402 | 18,795 | 25,505 | 17,341 |

| PAT | 4,409 | 1,700 | 7,153 | 13,883 | 18,834 | 14,185 |

| EPS (INR) | 24.16 | 9.32 | 39.18 | 77.34 | 105.26 | 79.20 |

| Net Worth | 41,216 | 42,636 | 48,738 | 58,531 | 76,123 | 92,211 |

Capital Market Data (as of June 30, 2026)

  • Face Value: INR 2.0 per share
  • Market Price: INR 851.55
  • Market Capitalization: INR 155,306.2 Mn
  • Shares Outstanding: 182.38 Mn
  • Shareholding Pattern: Mutual Funds (1.92%), Insurance Companies (3.64%), FPIs (16.99%), Bodies Corporate (1.53%)

Growth Strategy

  • Focus on complex and limited competition molecules with high entry barriers
  • Double-digit domestic business growth
  • Direct US market access through NATCO Pharma USA LLC
  • Scaling agri-business through product additions, R&D strengthening, and export market expansion
  • Demerger of CHS business to unlock shareholder value
  • New geography expansion through Adcock Ingram acquisition and strategic inorganic opportunities
  • Therapy diversification into infectious diseases, diabetes, and obesity
  • Advanced therapeutics including CAR-T, xenotransplantation, and antisense oligonucleotides